CN1235638C - 活性蛋白c制剂 - Google Patents

活性蛋白c制剂 Download PDF

Info

Publication number
CN1235638C
CN1235638C CNB988045672A CN98804567A CN1235638C CN 1235638 C CN1235638 C CN 1235638C CN B988045672 A CNB988045672 A CN B988045672A CN 98804567 A CN98804567 A CN 98804567A CN 1235638 C CN1235638 C CN 1235638C
Authority
CN
China
Prior art keywords
lyophilized formulations
sucrose
filler
sodium chloride
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988045672A
Other languages
English (en)
Chinese (zh)
Other versions
CN1254284A (zh
Inventor
A·D·卡尔森
T·A·舍利加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1254284A publication Critical patent/CN1254284A/zh
Application granted granted Critical
Publication of CN1235638C publication Critical patent/CN1235638C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB988045672A 1997-04-28 1998-04-24 活性蛋白c制剂 Expired - Fee Related CN1235638C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28
US60/045,255 1997-04-28
US60/045255 1997-04-28

Publications (2)

Publication Number Publication Date
CN1254284A CN1254284A (zh) 2000-05-24
CN1235638C true CN1235638C (zh) 2006-01-11

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988063824A Expired - Fee Related CN1227025C (zh) 1997-04-28 1998-04-24 改进的加工活化c蛋白的方法
CNB988045672A Expired - Fee Related CN1235638C (zh) 1997-04-28 1998-04-24 活性蛋白c制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB988063824A Expired - Fee Related CN1227025C (zh) 1997-04-28 1998-04-24 改进的加工活化c蛋白的方法

Country Status (34)

Country Link
US (4) US6159468A (https=)
EP (2) EP0875252B1 (https=)
JP (2) JP4383547B2 (https=)
KR (2) KR100450856B1 (https=)
CN (2) CN1227025C (https=)
AR (2) AR015598A1 (https=)
AT (1) ATE285788T1 (https=)
AU (2) AU743531B2 (https=)
BR (2) BR9809304B1 (https=)
CA (2) CA2287267C (https=)
CO (2) CO4940438A1 (https=)
CZ (1) CZ298429B6 (https=)
DE (1) DE69828330T2 (https=)
DK (1) DK0875252T3 (https=)
EA (2) EA004881B1 (https=)
EG (1) EG23685A (https=)
ES (1) ES2234072T3 (https=)
HU (2) HUP0003401A3 (https=)
ID (2) ID22933A (https=)
IL (2) IL132502A0 (https=)
IN (2) IN187157B (https=)
MY (2) MY118591A (https=)
NO (2) NO995134L (https=)
NZ (2) NZ500346A (https=)
PE (2) PE86299A1 (https=)
PL (2) PL195642B1 (https=)
PT (1) PT875252E (https=)
SI (1) SI0875252T1 (https=)
SV (2) SV1998000050A (https=)
TR (2) TR199902631T2 (https=)
TW (2) TW585871B (https=)
UA (2) UA55448C2 (https=)
WO (2) WO1998048822A1 (https=)
ZA (2) ZA983497B (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CZ298429B6 (cs) * 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CN1326355A (zh) * 1998-11-13 2001-12-12 伊莱利利公司 治疗肝素诱导的血小板减少症的方法
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
ATE232739T1 (de) * 1998-11-23 2003-03-15 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
CN1329503A (zh) * 1998-12-10 2002-01-02 伊莱利利公司 治疗血小板减少性紫癜和溶血性尿毒综合征的方法
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) * 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
EP1453529A4 (en) 2001-09-19 2007-09-26 Oklahoma Med Res Found TREATMENT OF SEPSIS WITH TAFI
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
EA200400548A1 (ru) 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
EP1485121A4 (en) * 2002-03-08 2007-11-07 Lilly Co Eli ACTIVE C PROTEIN FORMULATIONS
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
RU2329823C2 (ru) * 2002-10-29 2008-07-27 Алза Корпорейшн Стабилизированные твердые полипептидные частицы
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1641487B1 (en) * 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
EP1729791A2 (en) * 2004-03-17 2006-12-13 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
EP2029740B1 (en) * 2006-05-31 2012-06-20 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
CA2654761A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
BRPI0808259A2 (pt) * 2007-03-05 2014-07-08 Cadila Healthcare Ltd. , "formulação, processo de liofilização, formulação liofilizada, e processo para preparar uma formulação liofilizada"
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013151727A1 (en) 2012-04-03 2013-10-10 Smith Medical Asd, Inc. Heparin-bulking agent compositions and methods thereof
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP2017513944A (ja) 2014-04-16 2017-06-01 ジージー バイオテック エルエルシー 異常な皮膚瘢痕化の治療
CA2946032C (en) 2014-04-16 2022-06-14 Zz Biotech Llc Use of apc analogue for wound healing
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
CN109640961B (zh) * 2016-06-01 2021-11-02 施维雅知识产权英国有限公司 聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
CZ298429B6 (cs) 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
EA004881B1 (ru) 2004-08-26
PE84799A1 (es) 1999-09-16
CZ298429B6 (cs) 2007-10-03
US6162629A (en) 2000-12-19
TR199902529T2 (xx) 2000-02-21
CO4950523A1 (es) 2000-09-01
IL132325A0 (en) 2001-03-19
EP0875563A3 (en) 2000-08-02
ID22933A (id) 1999-12-16
HUP0100284A3 (en) 2003-08-28
CA2288143A1 (en) 1998-11-05
IL132325A (en) 2005-07-25
PT875252E (pt) 2005-03-31
PL336420A1 (en) 2000-06-19
SV1998000051A (es) 1998-12-11
KR20010020325A (ko) 2001-03-15
TR199902631T2 (xx) 2000-01-21
DK0875252T3 (da) 2005-04-25
PL195642B1 (pl) 2007-10-31
AU7258998A (en) 1998-11-24
BR9809304A (pt) 2000-10-17
US6436397B1 (en) 2002-08-20
KR100564189B1 (ko) 2006-03-27
EA199900979A1 (ru) 2000-06-26
CA2287267A1 (en) 1998-11-05
AR015598A1 (es) 2001-05-16
CN1261280A (zh) 2000-07-26
JP4383547B2 (ja) 2009-12-16
EP0875252A2 (en) 1998-11-04
DE69828330D1 (de) 2005-02-03
PE86299A1 (es) 1999-09-17
NO995198L (no) 1999-10-25
EA002149B1 (ru) 2001-12-24
BR9809304B1 (pt) 2011-02-08
CZ381099A3 (cs) 2000-03-15
TWI242443B (en) 2005-11-01
NZ337828A (en) 2001-06-29
HUP0100284A2 (hu) 2001-06-28
HUP0003401A2 (hu) 2001-02-28
JP2001524111A (ja) 2001-11-27
PL195090B1 (pl) 2007-08-31
UA55448C2 (uk) 2003-04-15
EA199900980A1 (ru) 2000-04-24
HK1016472A1 (en) 1999-11-05
PL336889A1 (en) 2000-07-17
HUP0003401A3 (en) 2003-01-28
MY120984A (en) 2005-12-30
CN1254284A (zh) 2000-05-24
BR9809292A (pt) 2000-07-04
CO4940438A1 (es) 2000-07-24
NO995134D0 (no) 1999-10-21
SV1998000050A (es) 1999-01-13
AU740753C (en) 2002-10-10
KR20010020242A (ko) 2001-03-15
EP0875563A2 (en) 1998-11-04
ATE285788T1 (de) 2005-01-15
ID23172A (id) 2000-03-23
ES2234072T3 (es) 2005-06-16
JP2001527543A (ja) 2001-12-25
EP0875252A3 (en) 2000-07-26
EP0875252B1 (en) 2004-12-29
KR100450856B1 (ko) 2004-10-02
IL132502A0 (en) 2001-03-19
MY118591A (en) 2004-12-31
TW585871B (en) 2004-05-01
JP4383546B2 (ja) 2009-12-16
CA2287267C (en) 2006-08-15
IN187157B (https=) 2002-02-16
CN1227025C (zh) 2005-11-16
AU740753B2 (en) 2001-11-15
DE69828330T2 (de) 2005-10-13
ZA983496B (en) 1999-10-25
WO1998048818A1 (en) 1998-11-05
EG23685A (en) 2007-05-09
US6395270B1 (en) 2002-05-28
NZ500346A (en) 2001-08-31
ZA983497B (en) 1999-10-25
IN183798B (https=) 2000-04-15
AU7161898A (en) 1998-11-24
CA2288143C (en) 2012-08-21
WO1998048822A1 (en) 1998-11-05
US6159468A (en) 2000-12-12
AU743531B2 (en) 2002-01-31
HU224826B1 (en) 2006-02-28
UA73071C2 (en) 2005-06-15
AR012010A1 (es) 2000-09-13
NO995198D0 (no) 1999-10-25
SI0875252T1 (en) 2005-06-30
NO995134L (no) 1999-12-21

Similar Documents

Publication Publication Date Title
CN1235638C (zh) 活性蛋白c制剂
US6630137B1 (en) Activated protein C formulations
JP6425674B2 (ja) 凍結乾燥した組換え型ｖｗｆ製剤
KR100491281B1 (ko) 저당함량을가지는안정한알부민무함유재조합인자Vlll의제제
FI85335C (fi) Foerfarande foer framstaellning av lyofiliserad, farmaceutisk vaevnadsplasminogenaktivator(t-pa)-komposition.
CN102046205A (zh) 具有延长的半衰期的因子ix缀合物
JP2002527490A (ja) 敗血症を治療する方法
CN105925545A (zh) 干燥转谷氨酰胺酶组合物
US20050143283A1 (en) Activated protein c formulations
JP2004511428A (ja) 凝固亢進状態を処置するための製剤および方法
CN1252726A (zh) 治疗血管疾病的方法
HK1016472B (en) Activated protein c formulations
EP1561469A1 (en) Activated Protein C Formulations
RU2257224C1 (ru) Способ получения концентрата плазмина человека и продукт для использования в медицине
CN1329503A (zh) 治疗血小板减少性紫癜和溶血性尿毒综合征的方法
CN1303428A (zh) 人蛋白c多肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060111